Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm Phase II Study of Panitumumab Rechallenge in Combination With Oxaliplatin or Irinotecan-based Chemotherapy in Patients With RAS Wild Type Advanced Colorectal Cancer.

NCT03311750 is registered in ClinicalTrials.gov with Hellenic Cooperative Oncology Group as lead sponsor.

NCT NCT03311750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03311750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm Phase II Study of Panitumumab Rechallenge in Combination With Oxaliplatin or Irinotecan-based Chemotherapy in Patients With RAS Wild Type Advanced Colorectal Cancer.
Lead sponsor
Hellenic Cooperative Oncology Group
Phase
Phase 2
Overall status
Terminated
Start date
March 26, 2018
Completion date
May 20, 2021
Enrollment
23 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer